Trial · NCT01114971
Labetalol and Esmolol: Vital Signs and Post Operative Pain Management
NCT01114971, Phase 4, Completed, Cedars-Sinai Medical Center; results first posted 2020-02-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Labetalol and Esmolol: Vital Signs and Post Operative Pain Management. Trials, record NCT01114971. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01114971
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Labetalol and Esmolol: Vital Signs and Post Operative Pain Management
- NCT number
- NCT01114971
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 75 participants, actual
- Lead sponsor
- Cedars-Sinai Medical Center
- Conditions
- Laparoscopic Surgery
- Interventions
- Fentanyl, Labetalol, Esmolol
- First posted
- 2010-05-03
- Last updated
- 2020-02-20
- Results first posted
- 2020-02-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Postoperative Pain | one day | Postoperative pain will be measured at PACU using a Verbal Rating Scale (VRS) from 0 to 10 VRS is a subjective measure in which individuals verbally rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain) |
| Secondary | Number of Participant With Opioid Consumption | 1 month | n=Post discharge use of opioid consumption NUMBER OF PARTICIPANTS WHO TOOK PAIN KILLER PILLS |
| Secondary | Postoperative Nausea and Vomiting | 1 day | Nausea and vomiting will be measured at PACU |
| Secondary | Return to Feeling Normal | 1 month | Days to report to return to feeling normal, using follow up questionnaires |
| Secondary | Patient Satisfaction Using a Verbal Rating Scale From 0 to 10 | 1 month | Patient satisfaction using a verbal rating scale from 0 to 10 Where a VRS is a subjective measure in which individuals verbally rated their level of satisfaction on an eleven-point numerical scale. The scale is composed of 0 (excellent satisfaction) to 10 |
| Secondary | Low Appetite | 1 month | Participant who experienced low appetite (follow up questionnaire) |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Postoperative Pain | one day | Score on scale 0-10 | MEAN | |
| SECONDARY | Number of Participant With Opioid Consumption | 1 month | participants | NUMBER | |
| SECONDARY | Postoperative Nausea and Vomiting | 1 day | participants | NUMBER | |
| SECONDARY | Return to Feeling Normal | 1 month | Days | MEAN | |
| SECONDARY | Patient Satisfaction Using a Verbal Rating Scale From 0 to 10 | 1 month | score on a scale (0-10) | MEAN | |
| SECONDARY | Low Appetite | 1 month | participants | NUMBER |
Source ClinicalTrials.gov
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Postoperative Pain | Fentanyl | 3.2 | Standard Deviation 2 | Score on scale 0-10 | |
| Postoperative Pain | Labetalol | 3 | Standard Deviation 3 | Score on scale 0-10 | |
| Postoperative Pain | Esmolol | 3.9 | Standard Deviation 2.5 | Score on scale 0-10 | |
| Number of Participant With Opioid Consumption | Fentanyl | 15 | participants | ||
| Number of Participant With Opioid Consumption | Labetalol | 14 | participants | ||
| Number of Participant With Opioid Consumption | Esmolol | 13 | participants | ||
| Postoperative Nausea and Vomiting | Fentanyl | 9 | participants | ||
| Postoperative Nausea and Vomiting | Labetalol | 4 | participants | ||
| Postoperative Nausea and Vomiting | Esmolol | 7 | participants | ||
| Return to Feeling Normal | Fentanyl | 11 | Standard Deviation 9 | Days |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Fentanyl | 25 | |
| Overall Study | STARTED | Labetalol | 25 | |
| Overall Study | STARTED | Esmolol | 25 | |
| Overall Study | COMPLETED | Fentanyl | 25 | |
| Overall Study | COMPLETED | Labetalol | 25 | |
| Overall Study | COMPLETED | Esmolol | 25 | |
| Overall Study | NOT COMPLETED | Fentanyl | 0 | |
| Overall Study | NOT COMPLETED | Labetalol | 0 | |
| Overall Study | NOT COMPLETED | Esmolol | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Fentanyl | 0 | 25 |
| Total, all-cause mortality | Labetalol | 0 | 25 |
| Total, all-cause mortality | Esmolol | 0 | 25 |
| Total, other adverse events | Fentanyl | 0 | 25 |
| Total, other adverse events | Labetalol | 0 | 25 |
| Total, other adverse events | Esmolol | 0 | 25 |
| Total, serious adverse events | Fentanyl | 0 | 25 |
| Total, serious adverse events | Labetalol | 0 | 25 |
| Total, serious adverse events | Esmolol | 0 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01114971
GET https://conductscience.org/api/trials/v1/NCT01114971/registered